# Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-07 16:29 UTC · Category: Business · Sources: 1 · Current Velocity: 0.25

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| news-medical.net | AI-designed drug candidate reverses biological age in clinical study | 2026-09-07 09:33 | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxOV3Zib1lEX2NVUEcwdEd4UWtOUnZScU5TS1REaUk4YmJKQnNtbGZERTZSRjVxTWljZkdhZk1TQUZCVmt2SXJTT1hQT0JybHc3UGk5WUZqQVNwUEJVWXFjaHNORjB5MWktR3pMaGd6UU52RTdtZGlqb0duaGV0VzBSNTFOU0pCZ3FxcVJXT2QtdE9ENjNYU2JuU1ZNNVV2MERNNms3TFlZcElud2gyb0F1WS1OZndhckU?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-07/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*